Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 375,087,136
  • Shares Outstanding, K 2,634,594
  • Annual Sales, $ 82,059 M
  • Annual Income, $ 15,119 M
  • 60-Month Beta 0.69
  • Price/Sales 4.57
  • Price/Cash Flow 12.37
  • Price/Book 6.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 1.46
  • Number of Estimates 7
  • High Estimate 1.55
  • Low Estimate 1.33
  • Prior Year 2.58
  • Growth Rate Est. (year over year) -43.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
137.02 +3.90%
on 06/26/20
149.17 -4.56%
on 06/11/20
-5.43 (-3.67%)
since 06/10/20
3-Month
137.02 +3.90%
on 06/26/20
157.00 -9.32%
on 04/23/20
+1.14 (+0.81%)
since 04/09/20
52-Week
109.16 +30.42%
on 03/23/20
157.00 -9.32%
on 04/23/20
+1.16 (+0.82%)
since 07/10/19

Most Recent Stories

More News
What Will Q2 Bank Earnings Reveal?

What Will Q2 Bank Earnings Reveal?

WFC : 25.47 (+5.95%)
ORCL : 57.39 (-0.24%)
NKE : 97.99 (+1.03%)
NFLX : 548.73 (+8.07%)
JPM : 96.27 (+5.47%)
JNJ : 142.37 (-0.08%)
IBM : 118.35 (+2.28%)
FDX : 158.59 (+1.83%)
C : 52.65 (+6.47%)
ADBE : 466.20 (+1.16%)
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod

Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.

JNJ : 142.37 (-0.08%)
GILD : 76.32 (+2.16%)
BMY : 57.43 (-1.17%)
FATE : 35.26 (-3.00%)
Top 3 Stocks Racing to Discover a Covid-19 Vaccine

AstraZeneca (AZN), Novavax (NVAX), and Johnson & Johnson (JNJ) are the three front runners to find a COVID-19 vaccine. The COVID-19 pandemic has affected roughly 12 million people and caused more than...

AZN : 53.76 (-0.39%)
NVAX : 94.36 (-2.01%)
JNJ : 142.37 (-0.08%)
Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals

Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.

JNJ : 142.37 (-0.08%)
AZN : 53.76 (-0.39%)
NVAX : 94.36 (-2.01%)
EBS : 94.23 (-0.26%)
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?

Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

JNJ : 142.37 (-0.08%)
Moderna Completes Enrollment in Phase II Coronavirus Study

Moderna (MRNA) is progressing well with its coronavirus vaccine development. It completes enrollment in a phase II study and finalizes phase III study protocol.

JNJ : 142.37 (-0.08%)
AZN : 53.76 (-0.39%)
MRNA : 62.61 (-3.63%)
CTLT : 78.01 (-1.44%)
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

JNJ : 142.37 (-0.08%)
Customer Interest in Wearable Devices Grows as Innovative Applications are Added

, /PRNewswire/ -- The wearable device market is largely driven by the increasing awareness of the importance of leading a healthy lifestyle and fitness. In addition, recent technological advancements...

INOTF : 0.0350 (unch)
NMRD : 7.76 (+0.78%)
CODX : 18.19 (+1.00%)
IBIO : 2.22 (-2.63%)
FLIR : 40.29 (+0.90%)
JNJ : 142.37 (-0.08%)
Novovax Up on $1.6B Federal Funding for Coronavirus Program

Novovax (NVAX) is evaluating a coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. A pivotal study is due to start in the fourth quarter.

JNJ : 142.37 (-0.08%)
MRK : 76.73 (+0.05%)
MRNA : 62.61 (-3.63%)
NVAX : 94.36 (-2.01%)
Johnson & Johnson (JNJ) Stock Moves -0.09%: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $142.85, marking a -0.09% move from the previous day.

JNJ : 142.37 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 143.67
1st Resistance Point 143.02
Last Price 142.37
1st Support Level 141.57
2nd Support Level 140.78

See More

52-Week High 157.00
Last Price 142.37
Fibonacci 61.8% 138.73
Fibonacci 50% 133.08
Fibonacci 38.2% 127.43
52-Week Low 109.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar